AU2483802A - Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases - Google Patents

Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases

Info

Publication number
AU2483802A
AU2483802A AU2483802A AU2483802A AU2483802A AU 2483802 A AU2483802 A AU 2483802A AU 2483802 A AU2483802 A AU 2483802A AU 2483802 A AU2483802 A AU 2483802A AU 2483802 A AU2483802 A AU 2483802A
Authority
AU
Australia
Prior art keywords
diagnosis
treatment
cell division
proliferative diseases
eukaryotic cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2483802A
Other languages
English (en)
Inventor
Christophe Echeverri
Pierre Goenczy
Anthony Hyman
Steven Jones
Karen Oegema
Matthew Kirkham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cenix BioScience GmbH
Original Assignee
Cenix BioScience GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cenix BioScience GmbH filed Critical Cenix BioScience GmbH
Publication of AU2483802A publication Critical patent/AU2483802A/xx
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C07K14/43545Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2483802A 2000-11-09 2001-11-09 Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases Pending AU2483802A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24675000P 2000-11-09 2000-11-09
PCT/EP2001/013034 WO2002038805A2 (en) 2000-11-09 2001-11-09 Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
AU2483802A true AU2483802A (en) 2002-05-21

Family

ID=22932039

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2483802A Pending AU2483802A (en) 2000-11-09 2001-11-09 Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases
AU2002224838A Ceased AU2002224838B9 (en) 2000-11-09 2001-11-09 Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2002224838A Ceased AU2002224838B9 (en) 2000-11-09 2001-11-09 Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases

Country Status (9)

Country Link
US (1) US7368248B2 (enExample)
EP (1) EP1334123B1 (enExample)
JP (1) JP2004526421A (enExample)
AT (1) ATE405585T1 (enExample)
AU (2) AU2483802A (enExample)
CA (1) CA2428438C (enExample)
DE (1) DE60135482D1 (enExample)
DK (1) DK1334123T3 (enExample)
WO (1) WO2002038805A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
JP2007511216A (ja) * 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
ATE452188T1 (de) 2004-02-10 2010-01-15 Sirna Therapeutics Inc Rna-interferenz-vermittelte hemmung der genexpression unter verwendung multifunktioneller sina (short interfering nucleic acid)
EP1747022A4 (en) 2004-04-23 2010-03-31 Univ Columbia INHIBITION OF HAIRLESS PROTEIN MRNA
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
CN101268194A (zh) 2005-09-20 2008-09-17 巴斯福植物科学有限公司 使用ta-siRNA调控基因表达的方法
HUE027018T2 (en) 2007-03-21 2016-08-29 Brookhaven Science Ass Llc Combination hairpin antisense compositions and methods for modulating expression
EP3406720A1 (en) 2009-12-18 2018-11-28 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat hsf1-related diseases
JP2013519869A (ja) 2010-02-10 2013-05-30 ノバルティス アーゲー 筋肉成長のための方法および化合物
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5162222A (en) * 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5155037A (en) * 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins

Also Published As

Publication number Publication date
WO2002038805A8 (en) 2007-07-05
WO2002038805A3 (en) 2003-02-13
CA2428438A1 (en) 2002-05-16
DE60135482D1 (de) 2008-10-02
US7368248B2 (en) 2008-05-06
EP1334123B1 (en) 2008-08-20
EP1334123A2 (en) 2003-08-13
JP2004526421A (ja) 2004-09-02
WO2002038805A2 (en) 2002-05-16
CA2428438C (en) 2012-09-25
DK1334123T3 (da) 2009-01-12
AU2002224838B9 (en) 2007-02-08
AU2002224838B2 (en) 2006-07-27
US20040048277A1 (en) 2004-03-11
ATE405585T1 (de) 2008-09-15

Similar Documents

Publication Publication Date Title
AU2483802A (en) Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases
UA85559C2 (en) Aminobenzophenone compounds
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
ATE286053T1 (de) Naphthyridinone zur hemmung der durch protein- tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
MY142067A (en) Xanthine derivatives as selective hm74a agonists, processes for the manufacture of said derivatives, formulations comprising these derivatives, and their use in the treatment of diseases where under-activation of the hm74a receptor contributes to the disease
WO2003009855A3 (de) Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
MXPA05005398A (es) Meta para terapia de deterioro cognitivo.
IL169897A0 (en) Sustituted heterocycles
EP2426203A3 (en) Agents useful in treating facioscapulohumeral muscular dystrophy
MY140132A (en) Thiazolidin-4-one derivatives for use in the treatment of anemias
YU50800A (sh) Derivati 2-(purin-9-il)-tetrahidrofuran-3,4-diola
NO20072548L (no) Xantinderivater med HM74A reseptoraktivitet
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
MX2022009759A (es) El uso de 1-(4-ciano-3-trifluorometil-fenil)-3-[7-(4-ciano-3-trifl uorometil-fenil)-6-tioxo-5-p-tolilo-5,7-diazaespiro[3.4]oct-8-ili deno]-tiourea.
PL356846A1 (en) Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase
TNSN08310A1 (en) Aurora kinase modulators and method of use
TW200510343A (en) Substituted dihydroquinazolines
DE60103171D1 (de) Verfahren und verbindungen zur behandlung proliferativer erkrankungen
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
MXPA04001720A (es) Acido nucleicos bv8 y polipeptidos con actividad mitogenica.
DE60210297D1 (de) Verwendung von long pentraxin ptx3 für die behandlung von infertilität bei frauen
TR200003596T2 (tr) Hipnotik beta-karbolin türevleri,hazırlanmaları için işlem ve tıbbi ürün olarak kullanımları
WO2002059611A3 (en) Diagnosis and treatment of cancer using mammalian pellino polypeptides and polynucleotides
WO2005025624A3 (en) The use of eukaryotic genes affecting cell cycle control or cell cycle progression for diagnosis and treatment of proliferattive diseases

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
SREP Specification republished